1. Home
  2. CNTN vs CVRX Comparison

CNTN vs CVRX Comparison

Compare CNTN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$2.00

Market Cap

146.5M

Sector

Health Care

ML Signal

N/A

Logo CVRx Inc.

CVRX

CVRx Inc.

HOLD

Current Price

$2.74

Market Cap

139.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
CVRX
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.5M
139.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CNTN
CVRX
Price
$2.00
$2.74
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$10.50
AVG Volume (30 Days)
700.3K
1.3M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
88.10
23.02
EPS
N/A
N/A
Revenue
N/A
$56,651,000.00
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$17.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.45
52 Week Low
$1.75
$2.20
52 Week High
$5.27
$11.30

Technical Indicators

Market Signals
Indicator
CNTN
CVRX
Relative Strength Index (RSI) 44.48 33.59
Support Level $1.75 $2.20
Resistance Level $3.80 $6.06
Average True Range (ATR) 0.13 0.34
MACD 0.04 -0.20
Stochastic Oscillator 77.94 16.58

Price Performance

Historical Comparison
CNTN
CVRX

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Share on Social Networks: